#18 Medical Robotics Breakthroughs: From Magnets to Heart Surgery

In partnership with

Ever thought about robots in surgery? No, they don’t argue over who gets the last coffee or call in sick. They just show up, stay precise, and save lives—kind of like that one ultra-reliable friend... if that friend had scalpels for hands.

Surgical Robots: When Magnets Meet Precision

Two surgical robots walked into an operating room... and performed a world-first procedure. No punchline here—just cutting-edge tech. Levita Magnetics’ MARS joined forces with Intuitive Surgical’s da Vinci SP for a prostate-removal surgery, proving that robots play well together when precision is on the line.

MARS isn’t just another robotic arm. It uses magnets to move organs inside the body, creating space for the da Vinci SP to operate. Think of it as a polite stagehand clearing the set while the star surgeon gets to work.

The da Vinci SP enters through a single incision, performing delicate tasks near critical nerves with robotic accuracy. Meanwhile, MARS holds everything steady, allowing the surgeon to focus solely on precision work.

Fewer cuts, less pain, and quicker recovery times — that’s what this robot duo delivers. MARS even frees up human assistants by managing tasks itself, like a coworker who actually helps instead of watching you struggle.

Levita Magnetics is already experimenting with augmented reality and 3D cameras for future surgeries. Remote-controlled operations might be closer than we think—doctors could soon say, "Let me sync up with my robot team."

Who knew combining two robot systems could transform complex procedures into something more efficient and less invasive? Looks like teamwork isn’t just for humans.

Build Smarter, Faster: AI Voice Agents for Every Industry

Save time building your AI calling assistant with Synthflow’s AI Voice Agent templates—pre-built, pre-tested, and ready for industries like real estate and healthcare. Get started fast with features like lead qualification and real-time booking. You can even create and sell your own templates to earn commissions!

Register Now

Microbot Medical's LIBERTY Surgical Robot Heads for FDA Approval

Microbot Medical Inc. has officially submitted its LIBERTY surgical robot for FDA 510(k) clearance, aiming to revolutionize endovascular procedures. If approved, LIBERTY will become the world's first single-use robotic system for these surgeries, potentially transforming how hospitals approach minimally invasive care.

LIBERTY isn’t just another gadget—it’s a fully disposable robotic system designed to handle neurovascular, cardiovascular, and peripheral vascular procedures. No bulky, expensive machines—just a compact design with remote control capabilities, keeping doctors safely out of the radiation zone. Think of it as the ultimate remote-controlled assistant, minus the "low battery" panic.

According to Harel Gadot, CEO of Microbot Medical, LIBERTY could target over 2 million peripheral vascular procedures performed yearly in the U.S., potentially reshaping this massive market.

The system’s ergonomic design is built to reduce physical strain on healthcare providers. No more awkwardly leaning over operating tables—doctors can control LIBERTY from a safe distance, making the workday a little easier and safer.

Microbot Medical expects FDA approval by Q2 2025. They’ve already completed their first human clinical trial at Brigham and Women’s Hospital in Boston, showing promising results. Add in successful pre-clinical tests and a recent $2.154 million settlement, and the company is moving full steam ahead.

With LIBERTY, Microbot Medical aims to cut costs, boost efficiency, and improve patient care—all while making robotic surgery more accessible.

Capstan Medical Secures $110M for Robotic Heart Surgery Trials

Capstan Medical Inc. has raised $110 million in a Series C funding round, boosting its total capital to over $150 million. This major investment supports the company’s mission to advance robotic heart surgery, with its first in-human mitral valve replacement procedure expected early next year.

The startup’s surgical robot targets mitral and tricuspid valve replacements, offering a less-invasive alternative to open-heart surgery. These procedures could be life-saving for patients not eligible for traditional surgeries. CEO Maggie Nixon confirmed that the mitral program is Capstan's top priority, with tricuspid trials set to follow in 2025.

Eclipse, Yu Galaxy, and Intuitive Ventures—long-time supporters—led the funding, joined by new investor Gideon Strategic Partners. Despite Intuitive Ventures’ backing, Nixon clarified that this is not a strategic partnership but purely a financial investment, ensuring Capstan remains independent.

The funds will fuel Capstan’s first-in-human procedures, pivotal trials, and regulatory preparations toward an expected FDA submission in 2028. This milestone allows them to move full speed ahead, advancing life-saving technology for heart disease—the world’s leading cause of death.

Capstan is also strengthening its executive team, recently appointing Brian King as finance chief, with regulatory leadership soon to follow. The company’s ambition is clear: reshape heart disease treatment through cutting-edge robotic solutions.